A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

计划入组 144 人 · 首次发布于 2020 年 11 月 25 日

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

计划入组 216 人 · 首次发布于 2021 年 5 月 24 日

Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence

计划入组 200 人 · 首次发布于 2014 年 2 月 25 日

Kallikrein Inhibitors (Toronto Innovation/Evotec)

Kallikrein inhibitors (BioCryst)

Kallikrein 5 inhibitors (netherton syndrome)

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

Masked T-Cell Engagers and Pasritamig Raise New Hope for Advanced Prostate Cancer Immunotherapy

J&J Highlights Solid Tumor Advances at WCLC and ESMO 2024

Johnson & Johnson's Pasritamig Shows Promising Anti-Tumor Activity in First-in-Human Prostate Cancer Trial